Pre-exposure prophylaxis for Hepatitis B virus treatment and HIV prevention

2026/05/05 by Maeve Barlow, Philippa Matthews, Stuart Flanagan +4 · 1 voice

paper · doi:10.6084/m9.figshare.32177877

openalex publication_date 2026/05/05 · openalex created_date 2026/05/06 · openalex updated_date 2026/07/01

Abstract

This is a poster to describe the population of people living with chronic Hepatitis B (PLHBV) who are accessing HIV pre-exposure prophylaxis (also known as PrEP) from Mortimer Market (London, UK), where our service provides care for people living with chronic (long-term) viral infections.These individuals may benefit from Tenofovir-based combination antiretroviral therapy for both HBV treatment HIV PrEP, and the benefits of PrEP are yet to be fully realised in this population.This information is helpful in shaping future ideas on how to provide wider/holistic care for PLWHB

Discussions

• Here is a link to our poster presenting use of #PrEP for #HIV #prevention & #HBV #treatment, presented at #BHIVABASHH26. Aiming for holistic, equitable care. #MedSky #HepSky #IDSky #NoHep #PublicHealt [bsky, 4 points, 0 comments]

Related

• HIV PrEP programmes as a framework for diagnosing and treating HBV infection in adolescents and young adults in KwaZulu-Natal, South Africa
• Time to Initiation of Hepatitis B Treatment is Reduced With the Use of the Xpert HBV Viral Load Kit
• Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: A case series and lessons for practice
• Driving progress towards PrEP equity: Key changes in the 2025 BASHH/BHIVA UK PrEP guidelines
• Hepatitis B Virus ( HBV ) Treatment Eligibility in the UK : Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines